Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: Paliperidone Palmitate (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Official(s) and/or principal investigator(s): Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary
The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations)
of i. m. paliperidone palmitate after administration in 2 different injection sites (deltoid
or gluteal).
Clinical Details
Official title: Pharmacokinetics, Tolerability, and Safety of Paliperidone After Repeated Intramuscular Injection of Paliperidone Palmitate in the Arm or the Buttock of Subjects With Schizophrenia
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To explore the comparability of pharmacokinetic parameter estimates of paliperidone and paliperidone palmitate between the 2 injection sites.
Secondary outcome: Incidence of adverse events, labs and ECGs throughout study.
Detailed description:
An i. m. paliperidone palmitate long-acting formulation is under development with the aim to
provide a sustained and stable level of paliperidone during each treatment cycle. The goal
of this study is to determine the similarity in pharmacokinetic (blood levels) and safety
profile after 2 intramuscular injections of paliperidone palmitate in the arm (deltoid
muscle) and the buttock (gluteal muscle), in the dose range that will be covered in later
Phase 3 trials (25 - 150 mg eq.). This is a repeated-dose, open-label, parallel group study
in patients with schizophrenia. The study consists of an up to 5-day screening period, an up
to 3-day tolerability period, a 14-day washout period, and a 64-day treatment period. As
paliperidone is the active metabolite of risperidone, all patients will be exposed to oral
risperidone during the screening period to confirm that they do not develop allergic
reactions to risperidone, and to help the investigator to assign patients to 1 of the 2
treatment doses. There will be a washout of at least 2 weeks after the last oral risperidone
intake before patients receive the first injection of paliperidone palmitate. Each treatment
group (arm or buttock injection) will receive 2 consecutive i. m. injections of the
long-acting formulation of paliperidone palmitate with a one-week interval. Whole blood
samples will be collected for the determination of paliperidone palmitate and paliperidone
concentrations in plasma. Whole blood samples will be obtained by venipuncture (needle
stick) immediately before (pre-dose) and at 4, 8, 12, 24, 48, 72, and 96 hours after the 1st
and 2nd injections of paliperidone palmitate. Following the collection of the 96-hour blood
sample after the 2nd injection, additional samples will be collected every 3 to 7 days
through the end of the 64-day treatment period. Safety will assessed throughout the study by
monitoring adverse events; changes in clinical laboratory results; tardive dyskinesia will
be rated using the Abnormal Involuntary Movement Scale (AIMS), akathisia will be rated
according to the Barnes Akathisia Rating Scale (BARS), extrapyramidal symptoms will be
evaluated using the Simpson-Angus Rating Scale (SAS); physical examinations;
electrocardiograms (ECGs); and patient evaluation of the injection site. Paliperidone
palmitate (25 or 150 mg eq.), 2 i. m. doses administered at a 1-week interval. Depending on
the randomized treatment group, each patient will receive 3 doses of oral risperidone:
either 1 mg once daily for 3 days or 2 mg once on the 1st day, 4 mg once on the 2nd day, and
6 mg once on the 3rd day.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with a diagnosis of schizophrenia
- clinically stable with no change in current antipsychotic medications
- meet PANSS score criteria
- have a body mass index (BMI) between 15 and 35 kilogram (kg)/meter (m)2.
Exclusion Criteria:
- Patients with DSM-IV diagnosis of alcohol or substance dependence, with the exception
of nicotine or caffeine dependence
- involuntarily-committed
- have moderately severe or severe EPS symptoms
- history of malignant neuroleptic syndrome
- have current suicidal ideation or demonstrates violence
- current presence of any significant or unstable medication condition
- treatment with any protocol disallowed therapies
- clinically significant result from screening laboratory or ECG.
Locations and Contacts
Additional Information
Starting date: August 2003
Last updated: April 26, 2010
|